MGNX · Macrogenics Inc
United States · RS rating 29 · As of 2026-11-03
| Price | 2.33 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 29 / 7 / 13 / 80 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 28 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +153.4% |
| Sales growth Q/Q | -43.4% |
| Distance from 52-week high | +52.1% |
| Market cap (USD) | $202.1M |